・業績
 ・受賞・表彰
 ・資格・認定
 ・認定施設
 業績 [ 2019年 ] 過去の業績はこちらから

原著論文(英文)
1. Fujibayashi A, Niwa T, Takeichi S, Suzuki K, Ohta H, Niwa A, Tsuchiya M, Yamamoto M, Hatakeyama D, Suzuki A, Baba H, Murakami N, Itoh Y. Clinical impact of a prospective audit with intervention and feedback without carbapenem restriction in patients receiving carbapenem injection. Int J Clin Pract. 73: e13262, 2019
2. Yoshida T, Yoshida S, Okada H, Suzuki A, Niwa T, Suzuki K, Ohmori T, Kobayashi R, Baba H, Suzuki K, Murakami N, Itoh Y, Ogura S. Risk factors for decreased teicoplanin trough concentrations during initial loading in critically ill patients. Pharmazie. 74: 120-124, 2019
3. Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. Cancer Chemother Pharmacol. 83: 123-129, 2019.
4. Iihara H, Shimokawa M, Abe M, Hayasaki Y, Fujita Y, Nagasawa Y, Sakurai M, Matsuoka R, Suzuki A, Morishige K. A study protocol for an open-label, single-arm, multicenter phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynecologic cancer patients. BMJ Open. 9: e024357, 2019
5. Iihara H, Fujii H, Yoshimi C, Kobayashi R, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A. Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome. Cancer Chemother Pharmacol. 83: 393-398, 2019.
6. Matsuhashi N, Takahashi T, Fujii H, Iihara H, Suetsugu T, Iwata Y, Tajima JY, Imai T, Mori R, Tanahashi T, Matsui S, Imai H, Tanaka Y, Yamaguchi K and Yoshida K. Preventive Effect and Safety of Pregabalin for FOLFOX-Related Peripheral Neurotoxicity in Patients with Advanced and Recurrent Colorectal Cancer: The Perpetual Study Estimated by United Sections in Gifu for Colorectal Cancer (Perseus CRC-01 Study). Clinics of Oncology. 1: 1-6, 2019
7. Yamada Y, Ohno Y, Niwa T, Kato-Hayashi H, Hayashi H, Ibuka T, Araki H, Sugiyama T, Shimizu M, Suzuki A. Rapid attainment of target trough concentrations of tacrolimus for early improvement of clinical symptoms in patients with ulcerative colitis. J Clin Pharm Ther. 44: 409-414, 2019
8. Ito-Takeichi S, Niwa T, Fujibayashi A, Suzuki K, Ohta H, Niwa A, Tsuchiya M, Yamamoto M, Hatakeyama D, Suzuki A, Baba H, Murakami N, Itoh Y. The impact of implementing an antifungal stewardship with monitoring of 1-3, β-D-glucan values on antifungal consumption and clinical outcomes. J Clin Pharm Ther. 44: 454-462, 2019
9. Niwa T, Yonetamari J, Hayama N, Fujibayashi A, Ito-Takeichi S, Suzuki K, Ohta H, Niwa A, Tsuchiya M, Yamamoto M, Hatakeyama D, Hayashi H, Obara M, Sugiyama T, Baba H, Suzuki A, Murakami N. Clinical impact of matrix-assisted laser desorption ionization-time of flight mass spectrometry combined with antimicrobial stewardship interventions in patients with bloodstream infections in a Japanese tertiary hospital. Int J Clin Pract. 73(5): e13332, 2019
(in press)
1. Horikawa Y, Suzuki A, Enya M, Hashimoto K, Nishida S, Kobayashi R, Ohashi, Yamazaki F, Totani R, Kobayashi H, Yamamoto M, Itoh Y, Takeda J. Evaluation of the Diabetes Regional Coordination Path using the Diabetes Coordination Notebook in community-based diabetes care. Diabetology International. (in press)
2. Horikawa Y, Suzuki A, Enya M, Hashimoto K, Nishida S, Kobayashi R, Ohashi T, Yamazaki F, Totani R, Kobayashi H, Yamamoto M, Itoh Y, Takeda J. Periodontal disease may be associated with the occurrence of diabetic retinopathy: A subgroup analysis of the survey of the Diabetes Coordination Notebook in Gifu. Exp Clin Endocrinol Diabetes. (in press)
3. Shibata Y, Miyahara Y, Sadaka Y, Yasue M, Fujimura M, Soda M, Yamamoto M, Kato H, Suzuki A, Tsukamoto K, Hara T, Tsurumi H, Kitaichi K. Evaluation of the effectiveness of caspofungin against febrile neutropenia and the factors related to the alteration in its plasma concentration. J Infect Chemother. (in press)
4. Hayashi H, Iihara H, Hirose C, Fukuda Y, Kitahora M, Kaito D, Yanase K, Endo J, Ohno Y, Suzuki A, Sugiyama T. Effects of Pharmacokinetics-related Genetic Polymorphisms on the Side Effect Profile of Afatinib in Patients with Non-Small Cell Lung Cancer. Lung Cancer. (in press)
5. Yamada Y, Fujii H, Ohata K, Kato-Hayashi H, Watanabe D, Ishihara D, Uemura S, Iwashita T, Imai H, Matsuhashi N, Takahashi T, Sugiyama T, Shimizu M, Yoshida K, Suzuki A. High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy. Med Oncol. (in press)

著書
1. 藤井宏典、飯原大稔.特集・Evidence Update 2019最新の薬物治療のエビデンスを付加的に利用する「エキスパートが注目する最新エビデンスをアップデート!:大腸癌治療薬」.薬局70:p167-172.南山堂、2019
2. 安田浩二、鈴木昭夫 (分担執筆).モデル・コアカリキュラムに沿った分かりやすい新実務実習テキスト 2019-2020.じほう、2019

学会報告(海外)
1. Gomyo T, Iihara H, Hayashi H, Endo J, Ito F, Yanase K, Kaito D, Sasaki Y, Sakai C, Hirose C, Fukuda Y, Sugiyama T, Suzuki A, Ohno Y. Relationship between severity of adverse events of afatinib and its pharmacokinetics and pharmacogenomics for EGFR mutation-positive non-small cell lung cancer. American Thoracic Society International Conference 2019 (May 2019, Dallas)
2. Hashimoto H, Abe M, Nakao M, Mizutani H, Sakata Y, Fujita Y, Nishimura T, Hirano K, Okada H, Inui N, Sakata Y, Iihara H, Zenda S, Uchitomi Y, Yamaguchi T, Hosina Y, Yanai T, Iwasa S, Yamamoto N, Ohe Y. A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin based chemotherapy (J-FORCE study). ASCO Annual Meeting (May 2019, Chicago). Oral Abstract Session, Best of ASCO.

学会報告(国内)
1. 志水真也、林祐一、西田承平、小林亮、鈴木昭夫.イホスファミド併用化学療法施行患者における中枢神経毒性の発現状況の検討.日本薬学会第139年会 (2019年3月、千葉)
2. 小林亮、山田紘嗣、山田悠人、鈴村祐司、鈴木昭夫.抗がん薬分解能を有する新規可視光応答型被膜の開発.日本薬学会第139年会 (2019年3月、千葉)

科学研究費助成金
1. [代表者]轟木堅一郎、[分担者]池袋一典、橋本博、林 秀樹、鈴木昭夫:科学研究補助金基盤研究(B) (19H03360):抗体特異的な核酸アプタマーの創出とバイオ・プロセス・クリニカルアナリシスへの活用;平成31-34年度
2. [代表者]塚田敬義、[分担者]村上啓雄、鈴木昭夫、谷口泰弘:科学研究補助金基盤研究(C) (19K10530):がん化学療法における適応外使用の新規審査アルゴリズムの開発;平成31-33年度
3. 石原正志:科学研究費奨励研究(19H00361):オピオイド誘発性便秘に対するナルデメジンの投与法の確立に関する研究.500千円
4. 鈴木景子:科学研究費奨励研究(19H00425):集中治療領域における内皮グリコカリックスの障害が抗菌薬の薬物動態に及ぼす影響.510千円

報道関係
1. 藤井宏典、丹羽隆、鈴木昭夫.「ASTと外来癌化学療法でエビデンスに基づく処方提案の実践」.Innovative Pharmacist VOL. 4 2019